FDA Issues CRL for Cingulate's CTx-1301 ADHD Treatment

The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) to CING Cingulate Inc. on June 2, 2026, for its New Drug Application (NDA) for CTx-1301, a daily dexmethylphenidate formulation for attention deficit hyperactivity disorder (ADHD). The PDUFA target action date had been May 31, 2026, following the FDA's acceptance of the NDA in October 2025. Cingulate's market value fell approximately $30 million on the news, reflecting investor disappointment with the regulatory setback.

Importantly, the CRL identified specific Chemistry, Manufacturing and Controls (CMC) information requests and did not raise any concerns about CTx-1301's clinical safety or efficacy. This distinction matters for investors: a CMC-only CRL is generally considered a more addressable regulatory issue than one involving clinical data gaps or labeling disputes. Cingulate said it expects a prompt resubmission addressing the FDA's requests and noted that the company remains well-capitalized with nearly $30 million in cash on hand. A Type A meeting with the FDA could help clarify the resubmission timeline in the coming weeks.

The CRL arrives against a broader backdrop of FDA regulatory activity in neurology. Herantis Pharma separately received positive FDA feedback on the Phase 2a study design for HER-096, its Parkinson's disease candidate, with the agency confirming readiness for clinical site activation and raising no concerns over chemistry, manufacturing, or preclinical data . While Herantis and Cingulate operate in different neurological indications, the contrasting outcomes on the same day illustrate the binary and company-specific nature of FDA regulatory decisions. Analysts will be watching Cingulate's resubmission timeline and any additional FDA guidance as the key near-term catalysts for CING.

Related Stocks

• CRL
• CMC
• INDV